The immunization coverage for the Measles-Containing-Vaccine Second-Dose (MCV2) in Germany has been steady, with a forecast of 93% from 2024 to 2028. This level represents a continuation from the year 2023, where MCV2 coverage also stood at 93%. Throughout the forecasted period, there is no year-on-year variation, indicating stability in the immunization efforts within the country. Over the last five years, the compound annual growth rate (CAGR) is 0%, highlighting consistent, unwavering coverage levels.
Future trends to watch for include potential policy changes impacting vaccine delivery and societal influences on vaccination uptake, as well as emerging public health challenges that could affect immunization strategies and resources. Monitoring these aspects will be crucial in maintaining or potentially increasing the coverage rates.
